We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Celtic Pharma Announces Results of a Phase III Program Evaluating XERECEPT® in Brain Tumors

News   Jun 08, 2009

 
Celtic Pharma Announces Results of a Phase III Program Evaluating XERECEPT® in Brain Tumors
 
 
 

RELATED ARTICLES

What Doesn't Kill Cells Makes Them Stronger

News

We’ve all heard the expression: “what doesn’t kill you makes you stronger.” Now, research suggests why, at a cellular level, this might be true. Brief exposures to stressors can be beneficial by prompting the cell to trigger sustained production of antioxidants, molecules that help get rid of toxic cellular buildup related to normal metabolism.



READ MORE

Enzyme Could Provide Biofuel Boost

News

Researchers at Tokyo Institute of Technology have honed in on an enzyme belonging to the glycerol-3-phosphate acyltransferase (GPAT) family as a promising target for increasing biofuel production from the red alga Cyanidioschyzon merolae.

READ MORE

Autism Linked to Egg Cells' Difficulty Creating Large Proteins

News

Genetic factors underlying fragile X syndrome, and potentially from other autism-related disorders, stem from defects in the cell's ability to create unusually large protein structures

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE